Nov 20 (Reuters) - Aptevo Therapeutics Inc :
* APTEVO THERAPEUTICS - FIRST PATIENT DOSED IN ONGOING RAINIER TRIAL ACHIEVED 90% REDUCTION IN LEUKEMIC BLASTS WITHIN THE FIRST 30 DAYS OF TREATMENT
* APTEVO THERAPEUTICS - FAVORABLE EARLY SAFETY, EFFICACY, TOLERABILITY,DURABILITY OF REMISSION DATA INFORMED CO'S ONGOING RAINIER PHASE 1B/2 TRIAL
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.